Brandes Investment Partners LP Cuts Stock Holdings in Smith & Nephew SNATS, Inc. $SNN

Brandes Investment Partners LP trimmed its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 5.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,181,183 shares of the medical equipment provider’s stock after selling 69,014 shares during the quarter. Brandes Investment Partners LP’s holdings in Smith & Nephew SNATS were worth $38,755,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in Smith & Nephew SNATS by 5.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after acquiring an additional 100,697 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Smith & Nephew SNATS by 139.9% during the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock worth $35,828,000 after purchasing an additional 575,666 shares during the period. Todd Asset Management LLC raised its stake in shares of Smith & Nephew SNATS by 30.2% during the 4th quarter. Todd Asset Management LLC now owns 944,578 shares of the medical equipment provider’s stock worth $30,992,000 after purchasing an additional 219,348 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Smith & Nephew SNATS by 45.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 937,943 shares of the medical equipment provider’s stock worth $34,038,000 after purchasing an additional 293,418 shares during the period. Finally, ABC Arbitrage SA raised its stake in shares of Smith & Nephew SNATS by 10.9% during the 4th quarter. ABC Arbitrage SA now owns 757,956 shares of the medical equipment provider’s stock worth $24,869,000 after purchasing an additional 74,504 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on SNN shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Monday, April 20th. Kepler Capital Markets cut Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Sanford C. Bernstein set a $31.85 target price on Smith & Nephew SNATS in a research note on Monday, May 11th. The Goldman Sachs Group reiterated a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Finally, Canaccord Genuity Group lowered their target price on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Smith & Nephew SNATS presently has an average rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Stock Up 3.3%

NYSE SNN opened at $31.34 on Wednesday. Smith & Nephew SNATS, Inc. has a one year low of $28.40 and a one year high of $38.79. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60. The business’s fifty day moving average is $31.36 and its 200-day moving average is $32.87.

Smith & Nephew SNATS (NYSE:SNN) last announced its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The firm had revenue of $1.60 billion during the quarter. As a group, equities research analysts anticipate that Smith & Nephew SNATS, Inc. will post 2.25 earnings per share for the current year.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.